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ABSTRACT
The antidepressant efficacy and safety of desvenlafaxine succinate were evaluated in two,
phase III, double-blind, placebo-controlled, flexible-dose studies. Outpatients with a
primary diagnosis of major depressive disorder were treated with desvenlafaxine
succinate or venlafaxine extended release. The primary outcome measure was the change
from baseline on the 17-item Hamilton Rating Scale for Depression. Secondary outcome
measures included the Clinical Global Impressions-Improvement Item scores,
Montgomery–Åsberg Depression Rating Scale score, Clinical Global Impressions Scale,
Severity of Illness score, 17-item Hamilton Rating Scale for Depression response rate,
percentage of patients in remission, visual analog scale-pain intensity overall pain and
subscale scores, 6-item Hamilton Rating Scale total score, Covi Anxiety Scale total score,
and the response rates on the Montgomery–Åsberg Depression Rating Scale and Clinical
Global Impressions Scale-Improvement Item Scale. At the end of eight weeks of
treatment, the pooled analyses revealed that desvenlafaxine was significantly better than
placebo on the 17-item Hamilton Rating Scale and the Clinical Global Impressions ScaleImprovement-Item scores. Adverse events were comparable to those found with other
drugs sharing a similar mechanism of action. These data provide support for the efficacy
and safety of desvenlafaxine in the treatment of major depressive disorder.

INTRODUCTION
Depression, a common mental disorder, is a major cause of disability throughout the
world, and a serious public health concern. Worldwide, more than 150 million people
suffer from depression, and nearly 1 million commit suicide every year. (WHO, 2001)
Even with treatment, a large percentage of patients who receive currently available
therapies recover only partially, often with continued functional impairment due to
residual symptoms, underscoring the importance of and need for novel antidepressants.
(Nelson et al., 2004, Thase et al., 2001, Steffens et al., 1997, Faravelli et al., 2003, Segal
et al., 2003)

Desvenlafaxine (O-desmethylvenlafaxine) is the major active metabolite of the
structurally novel antidepressant, venlafaxine. The succinate salt of desvenlafaxine is
being developed as a drug candidate for the treatment of major depressive disorder
(MDD). Desvenlafaxine succinate (desvenlafaxine) is chemically unrelated to tricyclic,
tetracyclic, or other available antidepressants (with the exception of venlafaxine) and is
classified as a dual-acting serotonin (5-HT) and norepinephrine (NE) reuptake inhibitor
(SNRI) because pre-clinical studies have demonstrated that it inhibits the neuronal uptake
of both 5-HT and NE and, to a lesser degree, dopamine reuptake. (Muth et al., 1991,
Clement et al., 1998) It does not have any monoamine oxidase (MAO) inhibitory activity,
and it shows virtually no affinity for rat brain muscarinic cholinergic, H1-histaminergic,
or α1-adrenergic receptors. (Deecher et al., 2006)

Desvenlafaxine has been examined in a series of preclinical in vivo and in vitro tests and
has been found to be active in multiple models used to predict antidepressant activity.
(Alfinito et al., 2006) Results of 2 phase III clinical trials showed that desvenlafaxine had
significantly better efficacy compared to placebo on the 17-item Hamilton Rating Scale
for Depression (HAM-D17), Clinical Global Impressions-Improvement scale scores (CGII), and the Montgomery–Åsberg Depression Rating Scale (MADRS). (DeMartinis et al.,
2007) (Septien-Velez L, 2007) (Montgomery and Asberg, 1979)

Both phase III studies discussed herein, which compared the antidepressant efficacy of
desvenlafaxine and placebo in MDD were, in retrospect, underpowered, largely due to
the high placebo response rate observed in both studies. To examine the efficacy of
desvenlafaxine in an adequately powered analysis, the data from both of these studies
were pooled post-hoc. Performing pooled analyses is in accordance with European
standards.

The results of both the pooled analysis using mixed-effect model for repeated measures
(MMRM) and the results of the individual studies are presented in this article.

METHODS
Two similar studies were performed—one in Europe (EU) and one in the United States
(US). Each was a double-blind, multi-site, placebo-controlled, parallel-group, venlafaxine
extended release (ER) referenced flexible-dose trial designed to compare the
antidepressant efficacy and safety of desvenlafaxine with placebo. After a screening

period of 6 to 14 days, eligible patients received up to 8 weeks of treatment. The use of
placebo was necessary to provide reliable scientific evidence of efficacy.

The designs of the EU and US protocols allowed for a 4-arm pooled analysis. The entry
criteria treatment protocol and other aspects of the study were similar with the exception
of the dosing of the active control. In both studies, desvenlafaxine was dosed from 200 to
400 mg daily, whereas the venlafaxine ER dosing in the EU study was 75 to 150 mg daily
and 150 to 225 mg daily in the US study. Because each study was designed to compare
desvenlafaxine to placebo, the differences in the dosing of the active control did not
affect the data analysis of the efficacy of desvenlafaxine.

The studies were approved by independent ethics committee (IEC) or Institutional
Review Board (IRB) and were consistent with Principles of Good Clinical Practice and
applicable regulatory requirements in each participating country. All participants
provided written informed consent before enrollment.

Selection of Study Population
Men and women, outpatients 18 to 75 years of age with a primary diagnosis of MDD,
based on a psychiatric interview using the Diagnostic and Statistical Manual of Mental
Disorders, Fourth Edition (DSM-IV) criteria, single or recurrent episode, without
psychotic features were eligible for study participation. At baseline and screening,
patients were also required to have a minimum HAM-D17 score of 22 and score at least 2
on item 1 (depressed mood) of HAM-D17, a Clinical Global Impressions Scale Severity

of Illness (CGI-S) score of at least 4, and a Raskin Depression Scale score greater than
the Covi Anxiety Scale score.

The screening evaluation included a medical history and a psychiatric history. The
modified Mini International Neuropsychiatric Interview (MINI) was used as a secondary
confirmation of the primary diagnosis of MDD and any comorbid psychiatric disorders
that may have been present. Patients with comorbid substance use disorders were
excluded; however, patients with comorbid generalized anxiety disorder, panic disorder,
or social anxiety disorder were allowed to participate as long as MDD was the primary
diagnosis. Patients at high risk for suicidal behaviors were excluded.

Dosing Schedule
Patients were randomly assigned to one of the treatment groups (desvenlafaxine,
venlafaxine ER, or placebo). Patients randomized to desvenlafaxine were treated with an
initial target dose of 200 mg. Patients in the EU study were started on the initial target
dose on day 1, while those in the US study received four days of 100 mg before reaching
the target dose. Each study had an optional increase to 400 mg after day 28 or decrease
back to 200 mg at any time, based on the investigator’s judgment. At the end of the study,
patients underwent a taper period based on their final dose.

Venlafaxine ER was used as an active control. In the EU study, patients assigned to
venlafaxine ER received 75 mg for 28 days, with an optional increase to 150 mg after day
28 based on the investigator’s judgment. In the US study, patients received a daily dose

of 75 mg daily for 4 days. This dose was increased to 150 mg on day 5, and there was an
optional increase to 225 mg after day 28. At the end of the study period, patients
underwent a taper period based on their final dose.

Study drug included 100 mg and 200 mg desvenlafaxine tablets, 75 mg venlafaxine ER
capsules, and matching placebo for each. Each patient received the assigned treatment in
individualized blister packs, using double dummy tablets and capsules.

Efficacy and Safety Evaluations
The primary efficacy measure was the HAM-D17 total score ascertained at each visit.
Secondary efficacy measures included the CGI-I score, the response rate as measured by
a 50% or greater decrease in the score on the HAM-D17, the percentage of patients in
remission (HAM-D17 scores of 7 or less), MADRS total score, CGI-S score, the visual
analog scale-pain intensity (VAS-PI) overall pain and subscale scores, HAM-D6 (Bech
version) total score, Covi Anxiety Scale total score, and the response rates on the
MADRS (decrease of 50% or more on the total score from baseline) and CGI-I.

Safety was determined using the following assessments: monitoring of adverse events
(AEs), discontinuation because of AEs, physical examination, standard 12-lead
electrocardiogram (ECG), vital signs (weight, pulse, and blood pressure), and laboratory
determinations (hematology, blood chemistry, and urinalysis).

Statistical Methods

Although the study designs of the US and EU studies were similar with the same duration
and efficacy measures, the dosing schedules of desvenlafaxine and venlafaxine ER were
different. The flexible dosing schedule of desvenlafaxine and placebo data allowed for
pooling. However, the venlafaxine ER dosing schedule was lower in the EU study (75
mg to 150 mg/day) than the US study (150 mg to 225 mg/day) and therefore, the
venlafaxine ER data are presented as 2 groups.

All efficacy analyses were based on the intent-to-treat (ITT) population, and the safety
analyses were based on the safety population.

The ITT population, or efficacy population, consisted of all randomized patients who had
a baseline primary evaluation, who took at least 1 dose of study drug and who had at least
1 primary efficacy evaluation after the first dose of study drug. The safety population
included all randomized patients who had taken at least 1 dose of study drug.

Longitudinal changes from baseline on pooled data for the primary efficacy measure
(HAM-D17 total) and the secondary measure CGI-I were analyzed using a MMRM
analysis. The change from baseline on the HAMD-17 was analyzed as the outcome
variable with treatment group, week, and the treatment group by week interaction as
fixed factors, center as a random factor, and baseline as a covariate. The CGI-I score was
analyzed as the outcome with treatment group, week, and the treatment group by week
interaction as fixed factors and center as a random factor. An autoregressive first order
[AR (1)] correlation structure was used to model the within subject correlations. The

MMRM analyzes all the data, taking into account the correlations between observations
for each patient and is unaffected by randomly missing data. As a secondary analysis,
changes from baseline to endpoint for both last observation carried forward (LOCF) and
observed cases were analyzed using an analysis of covariance (ANCOVA) with terms of
treatment, protocol, and baseline scores. A logistic regression model was used for binary
outcome variables (response and remission measured by the HAM-D17 and CGI-I).

When the studies were analyzed individually, the HAM-D17 total score was evaluated by
using ANCOVA on changes from baseline with treatment and site as the factors and
baseline scores as the covariate. LOCF and observed-cases analyses were both
performed. The CGI-I score was analyzed by using analysis of variance (ANOVA) with
treatment and site as the factors. Response and remission rates on the HAM-D17 were
analyzed with the logistic regression model, with treatment and site as the factors and
baseline score as a covariate. The HAM-D6 total score and Covi Anxiety Scale score
were evaluated by using ANCOVA on changes from baseline. Treatment effects were
tested at a two-sided significance level of 0.05.

STUDY PATIENTS
Disposition
A total of 738 patients (250 randomized to placebo, 239 to desvenlafaxine, 128 to
venlafaxine ER 75-150 mg, and 121 to venlafaxine ER 150-225 mg) were included in
this pooled analysis. Eighteen (18) patients had no data after baseline and were not
included in the safety population. The remaining 720 patients who completed the

prestudy period and took randomly assigned study drug under double-blind conditions
were included in the safety analyses. Seven patients of the safety population did not meet
criteria for the Intent-to-Treat (ITT) population, which included 713 patients. (Table 1)

Demographic and Other Baseline Characteristics
In the pooled analyses, 226, 127, 115 and 245 patients were evaluated in the
desvenlafaxine, venlafaxine ER 75 to 150 mg, venlafaxine ER 150 to 225 mg, and
placebo groups, respectively, with a mean age of 42 to 46 years. (Table 2) Reflecting the
geographic differences between the two pooled studies, minor differences in
demographic characteristics were seen among the patients. Individuals in the EU study
had a lower mean weight than those in the US study, and a greater percentage of patients
were non-Hispanic Caucasians. Because the magnitude of these differences was small,
they did not interfere with the use of the pooled analysis. Mean baseline severity on the
HAM-D17 ranged from 25.1 to 25.8 and did not show statistically significant differences
between groups.

RESULTS
Efficacy Evaluations
In the pooled analyses using MMRM, desvenlafaxine showed superior efficacy versus
placebo as measured by the change from baseline in the HAM-D17 score and the CGI-I
mean scores. A significant difference was observed at week 3 and was maintained
throughout the treatment period. (Figure 1) By the week 8 evaluation, desvenlafaxine
was significantly better than placebo in reducing MDD severity as measured by the

change from baseline in the HAM-D17 total scores (–14.21 versus –11.87 for
desvenlafaxine and placebo, respectively, p value 0.001). The magnitude of effect at
week 8 on MMRM was clinically significant at –2.34. Desvenlafaxine was also
significantly better than placebo as measured by the CGI-I (mean score of 1.9 versus 2.3,
respectively at week 8). (Figure 2)

Although the EU study failed on the primary efficacy endpoint using ANCOVA (LOCF),
desvenlafaxine and venlafaxine ER were significantly better than placebo at week 8 for
ANCOVA (OC data; p0.001 and p=0.027, respectively) and MMRM (p0.001 and
p=0.005, respectively), whereas in the US study, only venlafaxine ER separated from
placebo, using both ANCOVA (LOCF and OC) and MMRM.

At the final evaluation (ANCOVA), 55% of desvenlafaxine patients were HAM-D17
responders (50% reduction in HAM-D17 total score) compared with 47% of patients
who had received placebo. Thirty percent (30%) of patients on desvenlafaxine achieved
remission (HAM-D17 total score 7) compared with 23% of patients on placebo. (Figure
3) Final on therapy comparison between treatment groups showed desvenlafaxine was
significantly superior to placebo on the HAM-D6 Total and the back pain subscale score.
Venlafaxine ER 75-150 mg was superior to placebo on symptom improvement as
measured by the back pain and joint pain subscales as well as the and overall pain score.
Venlafaxine ER 150-225 mg was better than placebo for HAM-D6, MADRS total and
overall pain. (Table 3) Individual study results are presented in Tables 4 and 5.

Safety Results
The most common treatment emergent adverse events (TEAEs) included nausea,
somnolence, dry mouth, and sweating. The type and frequency of TEAEs reported were
similar to those reported with other SNRIs. (Table 6) In the desvenlafaxine group, there
were increases in mean serum lipids, blood pressure, and pulse compared to placebo and
decreases in mean weight. No deaths occurred in either study.

DISCUSSION
The results of this study confirm and extend results of 2 previous phase III studies of
desvenlafaxine. (DeMartinis et al., 2007) (Septien-Velez L, 2007) The first trial (N=461)
showed significant reduction in the HAM-D17 scores for the desvenlafaxine 100 mg
(p=0.0038) and 400 mg (p=0.0023) dose groups versus the placebo group. In the 200 mg
dose group, reduction in the HAM-D17 trended towards significance (p=0.0764). All
desvenlafaxine dose groups showed significant improvement on the CGI-I scale, a
secondary efficacy measure, compared with placebo (p< 0.05). (Septien-Velez L, 2007)
In the second phase III trial (N= 369), the adjusted mean change from baseline in the
HAM-D17 total score, the primary efficacy measure, was significantly greater for the
desvenlafaxine 200 mg (p=0.002) and 400 mg (p=0.008) dose groups versus placebo.
(p=0.053). (DeMartinis et al., 2007)

In the pooled analysis of the 2 underpowered studies described in this report,
desvenlafaxine was found to be effective compared with placebo on both the primary and
secondary efficacy measures. The efficacy of desvenlafaxine was also reflected in the

positive responder and remission analyses. Pooling of data from inconclusive placebocontrolled studies provides a useful method of establishing whether the treatment effect
observed was significant. The pooled analysis could only be carried out provided the
studies were comparable. In this case, the design of the studies was similar with the same
duration and the same primary and secondary scales. The flexible dosage regime for
desvenlafaxine was the same with the target treatment dose dependant on efficacy and
tolerability, and this allowed for pooling of data on desvenlafaxine and placebo. By
contrast, the dosage regime for the comparator, venlafaxine ER, was different in each
study, with a low dose of 75 mg to 150 mg a day in the EU study and a higher dose of
150 mg to 225 mg a day in the US study. The pooling of data allowed for valid
conclusions for the efficacy of desvenlafaxine but not for venlafaxine ER as a whole.

The ANCOVA, using LOCF method, which traditionally has been used as a primary
analysis in registration studies in EU and the US, uses the last recorded data point to
replace the missing points for a participant failing to complete the trial. This approach is
believed to be the most conservative because it can reduce the apparent efficacy by
assigning high scores for medications that are not well tolerated; however, recent
comparisons of different methods have demonstrated that this approach might not be the
best in all cases. (Mallinckrodt et al., 2004) The MMRM analysis is a type of likelihoodbased mixed-effects methods in which missing points are estimated based on observed
data. MMRM approaches are easy to implement, are more robust to the biases from
missing data, and provide better control of type I and type II errors than LOCF ANOVA.
(Mallinckrodt et al., 2004, Molenberghs et al., 2004)

The high placebo response observed in the 2 studies discussed herein reflects the
increasing placebo response observed in many studies over recent years. It has been
estimated that the proportion of patients in studies who respond to placebo has risen by
approximately 7% per decade (Walsh et al., 2002). A high placebo response in a study
makes it difficult, because of ceiling effects, to test for efficacy, as a larger number of
patients would be required for a valid comparison. Unless the power calculations for the
size of a study were constantly revised upwards to account for this difficulty, it is likely
that studies will be underpowered.

Placebo response is a major issue in clinical trials for psychiatric disorders. The causes of
a high placebo response in modern studies are many and varied and are the subject of
controversy. It is often claimed that the increased number of assessment visits and
increased non-specific contact and support, which are part of current high contact trial
practice, automatically increases the response rate on both placebo and active treatment
and raises the placebo response rate to a level where it is often difficult to distinguish
from active treatment. Similarly, the use of many assessment instruments and the careful
collection of adverse events have the consequence of increasing contact time with the
treatment team, and this may need to be more carefully controlled.

There is also evidence that the placebo response is higher in patients with mild to
moderate depression and lower in those with more severe depression; therefore the

inclusion of patients with more severe depression has been recommended as one means
of controlling the placebo response. (Fava et al., 1997)

The treatment effect—the magnitude of change on the pivotal scale of 1 antidepressant
compared to placebo—is also likely to be affected by the raised placebo response. The
treatment effect of desvenlafaxine observed in this analysis is 2.3 points on the HAM-D17,
which compares well with the treatment effect of between 2 and 3 points that has been
reported in positive pivotal placebo-controlled studies of recently licensed
antidepressants. (Khan et al., 2000, Storosum et al., 2001) The treatment effect of
desvenlafaxine in this pooled analysis is also in line with that observed with the
comparator venlafaxine ER, 75 mg to 150mg (2.4) and 150 mg to 225 mg (2.7) in
individual studies. These results suggest that treatment effects of desvenlafaxine and
venlafaxine ER in this analysis are clinically relevant. The clinical relevance of the
significant difference of the treatment effect observed on desvenlafaxine and venlafaxine
ER is also shown by the significant advantage compared to placebo measured on the CGI
severity and improvement scores, which represent the view of the independent clinician
who is making a clinical judgement of the individual patient under double-blind
conditions.

While the univariate repeated-measures ANOVA is still the most commonly used
statistical analysis tool for repeated measures in depression trials because of its simplicity
and familiarity, mixed-effects models have distinct advantages, including greater

flexibility. The differences in results between analytic methods is clearly demonstrated
in the EU and US studies, where in the pooled analyses, using MMRM, desvenlafaxine
was significantly more effective than placebo as measured by the HAM-D17, CGI-I, and
CGI-S at week 8. These results suggest that the mixed-effects approach, the use of which
has substantially increased over the last 10 years, may have important advantages over
traditional methods and may yield unbiased and more valid estimates. (Gueorguieva and
Krystal, 2004)

CONCLUSIONS
Desvenlafaxine was generally safe and well tolerated in this population. Pooled analyses
of the data with MMRM models demonstrate that desvenlafaxine was efficacious in the
treatment of MDD, despite the fact that the underpowered individual studies failed to
reach statistical significance.
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Table 1.

Summary of Patient Status: Number of Patients by Population Subset
Population Subset
Placebo
DVS 200VEN ER
VEN ER
400mg
75- 150mg 150-225mg
Randomized to
studies
No data after baseline
Safety populationa
Total ITTb
Non-ITT (includes
no-data patients
Completed doubleblind period

Total

250

239

128

121

738

5
245
245
5

8
231
226
13

1
127
127
1

4
117
115
6

18
720
713
25

210

166

108

90

574

Abbreviations: ITT=Intent to treat; DVS=desvenlafaxine ; VEN ER=venlafaxine ER
a. Safety population included all randomly assigned patients who received at least 1 dose of study drug.
b. The ITT population included all randomly assigned patients who received at least 1 dose of double-blind
study drug, had a baseline primary efficacy evaluation, and had a least 1 primary efficacy evaluation after the
first dose of double-blind study drug.

Table 2

Demographic and Baseline Characteristics: ITT Pooled Population
Placebo
n=245

DVS
200-400mg
n=226

VEN ER
75-150 mg
n=127

VEN ER
150-225mg
n=115

42 (12)
160 (65%)

43 (12)
153 (68%)

46 (12)
92 (72%)

42 (12)
80 (70%)

202 (82%)
80 (19.9)
25.5 (2.8)

202 (89%)
77 (21)
25.4 (2.9)

125 (98%)
72 (15)
25.8 (3.0)

89 (77%)
83 (22)
25.1 (2.4)

4.6 (0.6)

4.6 (0.6)

4.8 (0.6)

4.3 (0.5)

Characteristics
Age, mean (SD), years
Female, n (%)
Ethnicity/race, n (%)
White
Weight, mean (SD), kg
Baseline HAM-D17, total,
mean (SD)
Baseline CGI-S, mean (SD)

HAM-D17=17-item Hamilton Rating Scale for Depression; CGI-S= Clinical Global Impression-Severity of

Illness
DVS =desvenlafaxine ; VEN ER=venlafaxine ER

Table 3.
Secondary Efficacy Endpoints (LOCF, ANCOVA), Final Evaluation:
Pooled Population
Efficacy
Variable
MADRS
Total score

CGI-S

HAM-D6 Total

COVI Total

VAS Back Pain

Therapy
Group

n

Adjusted
Change
From
Baseline

Adjusted
Means
(95%CI)

P Value
Versus
Placebo

Placebo
DVS 200400mg
VEN ER 75150mg
VEN ER 150225mg

244

-13.5

17.5 (16.2,18.8)

-

223

-15.5

15.5 (14.2,16.9)

0.088

125

-16.0

15.0 (13.1.17.0)

0.108

113

-17.5

13.6 (11.4,15.7)

0.004

Placebo
DVS 200400 mg
VEN ER 75150mg
VEN ER 150225mg

245

-1.5

3.1 (2.9,3.3)

-

226

-1.7

2.9 (2.8,3.1)

0.368

127

-1.7

-2.9 (2.6,3.1)

0.326

115

-2.0

2.6 (2.3,2.9)

0.005

Placebo
DVS 200400mg
VEN ER 75150mg
VEN ER 150225mg

245

-5.7

7.6 (7.0,8.1)

-

226

-6.6

6.6 (6.0,7.2)

0.049

127

-6.6

6.6 (5.8,7.5)

0.175

115

-7.8

5.4 (4.5,63)

<0.001

Placebo
DVS SR 200400mg
VEN ER 75150mg
VENER
150225mg

244

-1.3

5.2 (5.0,5.3)

-

223

-1.4

5.0 (4.8,5.2)

0.782

125

-1.6

4.9 (4.6,5.2)

0.359

113

-1.6

4.9 (4.6,5.2)

0.431

Placebo
DVS 200400mg
VEN ER 75150mg
VEN ER 150225mg

244

-1.3

21.3 (18.8,23.8)

-

223

-1.4

15.4 (12.8,18.0)

0.782

125

-1.6

14.5 (10.7,18.4)

0.359

113

-1.6

16.9 (11.9,20.1)

0.431

Secondary Efficacy Endpoints (LOCF, ANCOVA), Final Evaluation: Pooled
Population (continued)
Efficacy
Variable
VAS Arms,
Legs, Joint Pain

VAS-PI
Overall Pain

Therapy
Group

n

Adjusted
Change
From
Baseline

Adjusted
Means
(95%CI)

P Value
Versus
Placebo

Placebo
DVS 200400mg
VEN ER 75100mg
VEN ER 150225mg

244

-9.2

20.5 (18.0,23.1)

-

221

-11.9

17.7(15.1,20.4)

0.321

125

-15.0

14.6 (10.7,18.5)

0.039

113

-15.2

14.5(10.3,18.7)

0.037

Placebo
DVS 200400mg
VEN ER 75100mg
VEN ER 150225mg

244

-9.5

22.0(19.5,24.6)

-

221

-11.8

19.8 (17.1,22.4)

0.478

125

-16.3

15.3 (11.4,19.1)

0.011

113

-13.9

17.7 (13.6,21.8)

0.178

MADRS=Montgomery-Åshberg Depression Rating Scale; CGI-S=Clinical Global Impression-Severity of Illness;
HAM-D6=Bech version of HAM-D17; VAS-PI=Visual Analog Scale Pain Intensity; DVS=desvenlafaxine; VEN
ER=venlafaxine ER

Table 4.
Efficacy Results (LOCF), Final Evaluation: ITT Individual Studies
Efficacy
Variable

HAM-D17 total
score
(ANCOVA)

Therapy
Group

EU
Placebo
DVS 200400mg
VEN ER 75100mg
US
Placebo
DVS 200400mg
VEN 150225mg

CGI-I Score
(ANOVA)

EU
Placebo
DVS 200400mg
VEN ER 75100mg
US
Placebo
DVS 200400mg
VEN ER 150225mg

n

Adjusted
Mean
Change from
Baseline

Difference in
Adjusted
Means (95%
CI) versus
Placebo

P
Value
versus
DVS
SR

P
Value
versus
VEN
ER

120

-12.5

–

0.381

0.171

116

-13.4

0.9 (-1.1, 2.8)

127

-13.8

1.3 (-0.6, 3.2)

125

-9.78

–

0.488

0.005

110

-10.5

0.7 (-1.3, 2.7)

115

-12.6

2.9 (0.9, 4.9)

120

2.3 (2.1, 2.5)

–

0.404

0.107

116

2.2 (1.9, 2.4)

0.1 (-0.2, 0.4)

127

2.0 (1.8, 2.3)

0.2 (-0.1, 0.5)

125

2.5 (2.3, 2.8)

-0.1 (-0.2, 0.4)

0.604

0.011

110

2.5 (2.2, 2.7)

0.4 (0.1, 0.7)

115

2.1 (1.9, 2.4)

Abbreviations: ANCOVA=analysis of covariance; ANOVA=analysis of variance; CI=confidence intervals; HAMD17=17-item Hamilton Rating Scale for Depression; CGI-I=Clinical Global Impressions Scale-Improvement; LOCF=
last observation carried forward; DVS =desvenlafaxine ; VEN ER=venlafaxine ER

Table 5.
HAM-D17 Response and Remission Rates, Final Evaluation: Individual Studies
Efficacy Variable
HAM-D17
Response

Therapy Group
EU
Placebo
DVS 200400mg
VEN ER 75100mg
US
Placebo
DVS 200400mg
VEN ER 150225mg

HAM-D17
Remission

EU
Placebo
DVS 200400mg
VEN ER 75100mg
US
Placebo
DVS 200400mg
VEN ER 150225mg

Proportion of
Responders (%)

OR (Adjusted
Odds Ratio
95% CI)

P Value versus
Placebo

60 (50)

–

–

69 (59)

1.507 (0.89, 2.55)

0.126

81 (64)

1.772 (1.06, 2.97)

0.03

55 (44)

–

–

55 (50)

1.248 (0.74, 2.11)

0.408

66 (57)

1.738 (1.03, 2.93)

0.038

30 (25)

–

–

39 (34)

1.549 (0.87, 2.76)

0.138

43 (34)

1.553 0.88, 2.73)

0.127

26 (21)

–

–

29 (26)

1.331 (0.71, 2.48)

0.369

41 (36)

2.191 (1.21, 3.98)

0.01

HAM-D17=17-item Hamilton Rating Scale for Depression; CI=confidence interval; DVS =desvenlafaxine
VEN ER=venlafaxine ER

Table 6.

Most Common TEAEs (5% and at Least 2 Times Greater with DVS Than with
Placebo): Pooled and Individual Populations
VEN ER
Adverse Event
Placebo
DVS
75-150 mg
VEN ER
200-400 mg
n=127
150-225 mg
n=245
n=231
n=117
Nausea
Somnolence
Dry mouth
Sweating
Asthenia
Constipation
Abnormal vision
Anorexia
Vomiting
Tachycardia
Impotence
(men only)

30 (12)
16 (7)
10 (4)
10 (4)
10 (4)
7 (3)
3 (1)
3 (1)
2 (1)
2 (1)
1 (1)

87 (38)
31 (13)
47 (20)
45 (20)
21 (9)
32 (14)
13 (6)
23 (10)
17 (7)
13 (6)
7 (9)

27 (21)
12 (9)
17 (13)
12 (9)
10 (8)
6 (5)
3 (2)
6 (5)
3 (2)
0
2 (6)

TEAEs = treatment-emergent adverse events
DVS = desvenlafaxine; VEN ER=venlafaxine ER
 Incidence based on the number of men: placebo=85, desvenlafaxine =75, and venlafaxine ER=71

34 (29)
22 (19)
30 (26)
21 (18)
7 (6)
9 (8)
5 (4)
18 (15)
3 (3)
5 (4)
4 (11)

LEGENDS
Figure 1. Mean Change from Baseline of HAM-D17 Total Score Over Time, MMRM:
Pooled Population
Figure 2. Efficacy Results, MMRM, Week 8 Evaluation: Pooled Population
Figure 3. HAM-D17 Response and Remission Rates, Final Evaluation: Pooled Population
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